The management of<unk>  revolves around 3 main components: acutely managing DKA, identification of<unk>  subtype, and longterm diabetic management similar to that in type 2 diabetes. As patients are likely to initially present in DKA, the acute management of DKA is the first priority. The treatment of DKA in<unk>  is identical to the treatment of DKA caused by type 1 diabetes and revolves around fluid repletion, electrolyte repletion, and administration of insulin. After the resolution of the DKA episode consideration of what patients to test for<unk>  should be considered. Most providers would recommend testing for autoantibodies in any patient presenting with a DKA episode, and this thought<unk> ss should be followed especially in patients who do not fit a classic type 1 diabetes picture of a young patient with classical diabetic symptoms. In order to get a full Aβ diagnosis presence of beta cell function must also be completed using C-peptide levels. After diagnosing the subtype of<unk> , long term management with a primary care provider should be done with diabetic education and counseling as patients will require insulin therapy after initial presentation. Routine followups serve an important role during this time to evaluate the changing insulin needs of the patient. Due to the<unk> nsity for DKA, insulin is a staple of<unk>  management, and other anti-glycemic agents should only be added if glucose levels rise while on effective insulin therapy.
Ketosis-prone diabetes
Diabetic hypoglycemia
Lifestyle causes of type 2 diabetes
Idiopathic hypoglycemia
Steroid diabetes
Lipoatrophic diabetes
Non-islet cell tumor hypoglycemia
Reactive hypoglycemia